1. Transcriptional profiling of inductive mesenchyme to identify molecules involved in prostate development and disease.
    Vanpoucke, G; Orr, B; Grace, OC; Chan, R; Ashley, GR; Williams, K; Franco, OE; Hayward, S; Thomson, AA
    Genome Biol. 2007;8(10):R213.| Pubmed
  2. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.
    Blenkiron, C; Goldstein, LD; Thorne, NP; Spiteri, I; Chin, SF; Dunning, MJ; Barbosa-Morais, NL; Teschendorff, AE; Green, AR; Ellis, IO; Tavare, S; Caldas, C; Miska, EA
    Genome Biol. 2007;8(10):R214.link| Pubmed
  3. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas.
    van Duin, M; van Marion, R; Vissers, KJ; Hop, WCJ; Dinjens, WNM; Tilanus, HW; Siersema, PD; van Dekken, H
    Cytogenet Genome Res. 2007;118(2-4):130-7.| Pubmed
  4. A role for glial cell-derived neurotrophic factor-induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.
    Esseghir, S; Todd, SK; Hunt, T; Poulsom, R; Plaza-Menacho, I; Reis-Filho, JS; Isacke, CM
    Cancer Res. 2007 Dec 15;67(24):11732-41.| Pubmed
  5. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.
    Xiang, Y; Zhu, Z; Han, G; Ye, X; Xu, B; Peng, Z; Ma, Y; Yu, Y; Lin, H; Chen, AP; Chen, CD
    Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19226-31. Epub 2007 Nov 28.| Pubmed
  6. A mechanism misregulating p27 in tumors discovered in a functional genomic screen.
    Garrett-Engele, CM; Tasch, MA; Hwang, HC; Fero, ML; Perlmutter, RM; Clurman, BE; Roberts, JM
    PLoS Genet. 2007 Dec;3(12):e219.| Pubmed
  7. Selective Raf inhibition in cancer therapy.
    Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA.
    Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. | Pubmed
  8. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
    Dubovsky JA, McNeel DG.
    Prostate. 2007 Dec 1;67(16):1781-90. | Pubmed
  9. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
    Wu, MH; Soler, DR; Abba, MC; Nunez, MI; Baer, R; Hatzis, C; Llombart-Cussac, A; Llombart-Bosch, A; Aldaz, CM
    Mol Cancer Res. 2007 Dec;5(12):1285-95.| Pubmed
  10. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin.
    Leong, KG; Niessen, K; Kulic, I; Raouf, A; Eaves, C; Pollet, I; Karsan, A
    J Exp Med. 2007 Nov 26;204(12):2935-48. Epub 2007 Nov 5.| Pubmed
  11. Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?
    Sharifi, N; Lechleider, RJ; Farrar, WL
    J Mol Endocrinol. 2007 Nov;39(5):329-32.| Pubmed
  12. Identification of novel pathway partners of p68 and p72 RNA helicases through Oncomine meta-analysis.
    Wilson BJ, Giguère V.
    BMC Genomics. 2007 Nov 15;8:419.| Pubmed
  13. Heat shock protein B8, a cyclin-dependent kinase-independent cyclin D1 target gene, contributes to its effects on radiation sensitivity.
    Trent S, Yang C, Li C, Lynch M, Schmidt EV.
    Cancer Res. 2007 Nov 15;67(22):10774-81. | Pubmed
  14. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.
    Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM.
    Cancer Cell. 2007 Nov;12(5):419-31.| Pubmed
  15. Understanding systemic sclerosis through gene expression profiling.
    Pendergrass, SA; Whitfield, ML; Gardner, H
    Curr Opin Rheumatol. 2007 Nov;19(6):561-7.| Pubmed
  16. Meta- and gene set analysis of stomach cancer gene expression data.
    Kim, S; Kim, J; Lee, H; Noh, S; Song, K; Cho, J; Jeong, H; Kim, WH; Yeom, Y; Kim, N; Kim, S; Yoo, H; Kim, YS
    Mol Cells. 2007 Oct 31;24(2):200-9.| Pubmed
  17. Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion.
    Darwiche, N; Ryscavage, A; Perez-Lorenzo, R; Wright, L; Bae, DS; Hennings, H; Yuspa, SH; Glick, AB
    Oncogene. 2007 Oct 18;26(48):6885-95. Epub 2007 May 21.| Pubmed
  18. JMJD3 is a histone H3K27 demethylase.
    Xiang, Y; Zhu, ZQ; Han, G; Lin, HQ; Xu, LY; Chen, CD
    Cell Res. 2007 Oct;17(10):850-7.| Pubmed
  19. Claudin-7 immunohistochemistry in renal tumors - A candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
    Hornsby, CD; Cohen, C; Amin, MB; Picken, MM; Lawson, D; Yin-Goen, QQ; Young, AN
    Arch Pathol Lab Med. 2007 Oct;131(10):1541-6.| Pubmed
  20. A latent variable approach for meta-analysis of gene expression data from multiple microarray experiments.
    Choi H, Shen R, Chinnaiyan AM, Ghosh D.
    BMC Bioinformatics. 2007 Sep 27;8:364.| Pubmed
  21. Identification of five human novel genes associated with cell proliferation by cell-based screening from an expressed cDNA ORF library.
    Ma, X; Wang, X; Gao, X; Wang, L; Lu, Y; Gao, P; Deng, WW; Yu, P; Ma, JJ; Guo, JH; Cheng, HL; Zhang, CY; Shi, TP; Ma, DL
    Life Sci. 2007 Sep 15;81(14):1141-51. Epub 2007 Aug 17.| Pubmed
  22. Integrative analysis of genomic aberrations associated with prostate cancer progression.
    Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
    Cancer Res. 2007 Sep 1;67(17):8229-39.| Pubmed
  23. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
    Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB.
    Cancer Res. 2007 Sep 1;67(17):7991-5.| Pubmed
  24. Thymosin beta-NB is the human isoform of rat thymosin beta 15.
    Banyard, J; Hutchinson, LM; Zetter, BR
    Ann N Y Acad Sci. 2007 Sep;1112:286-96. Epub 2007 Jun 13.| Pubmed
  25. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
    Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M.
    Mol Cell. 2007 Aug 3;27(3):380-92.| Pubmed
  26. Cellular functions of 14-3-3zeta in apoptosis and cell adhesion emphasize its oncogenic character.
    Niemantsverdriet M, Wagner K, Visser M, Backendorf C.
    Oncogene. 2008 Feb 21;27(9):1315-9. Epub 2007 Aug 20.| Pubmed
  27. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior.
    Degen M, Brellier F, Kain R, et al.
    Cancer Research 67 (19): 9169-9179 Oct 1 2007| Pubmed
  28. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status.
    Abba MC, Sun H, Hawkins KA, et al.
    Molecular Cancer Research 5 (9): 881-890 Sep 2007| Pubmed
  29. Integrative genomic analysis of phosphatidylinositol 3 ‘-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer.
    Zhang L, Huang J, Yang N, et al.
    Clinical Cancer Research 13 (18): 5314-5321 Part 1 Sep 15 2007| Pubmed
  30. The la autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.
    Al-Ejeh F, Darby JM, Brown MP
    Clinical Cancer Research 13 (18): 5509s-5518s Part 2 Suppl. S Sep 15 2007| Pubmed
  31. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.
    Nature. 2007 Aug 2;448(7153):595-9.| Pubmed
  32. The lethal phenotype of cancer: the molecular basis of death due to malignancy.
    Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ.
    CA Cancer J Clin. 2007 Jul-Aug;57(4):225-41. Review. Erratum in: CA Cancer J Clin. 2007 Nov-Dec;57(6):380.| Pubmed
  33. UTRN on chromosome 6q24 is mutated in multiple tumors.
    Li Y, Huang J, Zhao YL, et al.
    Oncogene 26 (42): 6220-6228 Sep 13 2007| Pubmed
  34. Expression of interleukin-13 receptor alpha 2 in glioblastoma multiforme: Implications for targeted therapies.
    Jarboe JS, Johnson KR, Choi Y, et al.
    Cancer Research 67 (17): 7983-7986 Sep 1 2007| Pubmed
  35. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.
    O’Neill CF, Urs S, Cinelli C, et al.
    American Journal of Pathology 171 (3): 1023-1036 Sep 2007| Pubmed
  36. Protein 4.1B suppresses prostate cancer progression and metastasis.
    Wong SY, Haack H, Kissil JL, et al.
    Proceedings of The National Academy of Sciences of The United States of America 104 (31): 12784-12789 Jul 31 2007| Pubmed
  37. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
    Wang QB, Li W, Liu XS, et al.
    Molecular Cell 27 (3): 380-392 Aug 3 2007| Pubmed
  38. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.
    Tedesco D, Zhang JH, Trinh L, et al.
    Neoplasia 9 (7): 601-u4 Jul 2007| Pubmed
  39. Pre- and post-initiation chemoprevention activity of 2-alkyl/aryl selenazolidine-4(R)-carboxylic acids against tobacco-derived nitrosamine (NNK)-induced lung tumors in the A/J mouse.
    Franklin MR, Moos PJ, El-Sayed WM, et al.
    Chemico-Biological Interactions 168 (3): 211-220 Jul 20 2007| Pubmed
  40. Evidence for systems-level molecular mechanisms of tumorigenesis.
    Hernandez P, Huerta-Cepas J, Montaner D, et al.
    BMC Genomics 8: Art. No. 185 Jun 20 2007| Pubmed
  41. Expression of Ral GTPases, their effectors, and activators in human bladder cancer.
    Smith SC, Oxford G, Baras AS, et al.
    Clinical Cancer Research 13 (13): 3803-3813 Jul 1 2007| Pubmed
  42. Large-scale integration of cancer microarray data identifies a robust common cancer signature.
    Xu L, Geman D, Winslow RL
    BMC Bioinformatics 8: Art. No. 275 Jul 30 2007| Pubmed
  43. Characterization of protein-interaction networks in tumors.
    Platzer A, Perco P, Lukas A, et al.
    BMC Bioinformatics 8: Art. No. 224 Jun 27 2007| Pubmed
  44. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer.
    Paulson KE, Rieger-Christ K, McDevitt NA, et al.
    Cancer Research 67 (13): 6136-6145 Jul 1 2007| Pubmed
  45. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.
    Lange K, Kammerer M, Hegi ME, et al.
    Cancer Research 67 (13): 6163-6173 Jul 1 2007| Pubmed
  46. Metastasis-associated protein 1 transgenic mice: A new model of spontaneous B-Cell lymphornas.
    Bagheri-Yarmand R, Balasenthil S, Gururaj AE, et al.
    Cancer Research 67 (15): 7062-7067 Aug 1 2007| Pubmed
  47. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.
    Kim B, Lee HJ, Choi HY, et al.
    Cancer Research 67 (15): 7431-7438 Aug 1 2007| Pubmed
  48. DGEM - A Microarray gene expression database for primary human disease tissues.
    Xia YN, Campen A, Rigsby D, et al.
    Molecular Diagnosis & Therapy 11 (3): 145-149 2007| Pubmed
  49. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
    Am J Surg Pathol. 2007 Jun;31(6):882-8.| Pubmed
  50. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
    J Pathol. 2007 May;212(1):91-101.| Pubmed
  51. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
    Warnat P, Oberthuer A, Fischer M, et al.
    BMC Cancer 7: Art. No. 89 May 25 2007| Pubmed
  52. CKAP2 is a spindle-associated protein degraded by APC/C-cdh1 during mitotic exit.
    Seki A, Fang GW
    Journal of Biological Chemistry 282 (20): 15103-15113 May 18 2007| Pubmed
  53. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34.
    Abba MC, Fabris VT, Hu YH, et al.
    Cancer Research 67 (9): 4104-4112 May 1 2007| Pubmed
  54. Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME.
    Finocchiaro G, Mancuso FM, Cittaro D, et al.
    Nucleic Acids Research 35 (7): 2343-2355 Apr 2007| Pubmed
  55. CCR2 expression correlates with prostate cancer progression.
    Lu Y, Cai Z, Xiao GZ, et al.
    Jrl of Cellular Biochemistry 101 (3): 676-685 JUN 1 2007| Pubmed
  56. Mass spectrometry-based “omics” technologies in cancer diagnostics.
    Zhang XW, Wei D, Yap Y, et al.
    Mass Spectrometry Rvws 26 (3): 403-431 MAY-JUN 2007| Pubmed
  57. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis.
    Ma WB, Stafford LJ, Li DL, et al.
    Jrl of Cellular Biochemistry 100 (6): 1376-1386 APR 15 2007| Pubmed
  58. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
    Chen GA, Wang XJ, Yu JJ, et al.
    Cancer Research 67 (7): 3461-3467 APR 1 2007| Pubmed
  59. 5-aza-2 ‘-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.
    Zorn CS, Wojno KJ, McCabe MT, et al.
    Clinical Cancer Research 13 (7): 2136-2143 APR 1 2007| Pubmed
  60. Feature selection and molecular classification of cancer using genetic programming.
    Yu JJ, Yu JD, Almal AA, et al.
    Neoplasia 9 (4): 292-U16 APR 2007| Pubmed
  61. Role of the chromobox protein CBX7 in lymphomagenesis.
    Scott CL, Gil J, Hernando E, et al.
    Proceedings of The National Academy of Sciences of The United States of America 104 (13): 5389-5394 MAR 27 2007| Pubmed
  62. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
    Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.
    Mod Pathol. 2007 May;20(5):538-44. Epub 2007 Mar 2.| Pubmed
  63. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor.
    Stabile H, Mitola S, Moroni E, et al.
    Blood 109 (5): 1834-1840 MAR 1 2007| Pubmed
  64. LRIG-inhibitors of growth factor signalling - double-edged swords in human cancer?
    Hedman H, Henriksson R
    European Journal of Cancer 43 (4): 676-682 MAR 2007| Pubmed
  65. Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silico analysis.
    Sadanandam A, Varney ML, Kinarsky L, et al.
    Omics-a Jrl of Integrative Biology 11 (1): 41-57 MAR 2007| Pubmed
  66. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.
    Rody A, Holtrich U, Gaetje R, et al.
    Clinical Cancer Research 13 (4): 1115-1122 FEB 15 2007| Pubmed
  67. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
    Podar K, Raab MS, Tonon G, et al.
    Cancer Research 67 (4): 1680-1688 FEB 15 2007| Pubmed
  68. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.
    Lin KY, Lu D, Hung CF, et al.
    Cancer Research 67 (4): 1832-1841 FEB 15 2007| Pubmed
  69. TGFBR3 loss and consequences in prostate cancer.
    Sharifi N, Hurt EM, Kawasaki BT, et al.
    Prostate 67 (3): 301-311 FEB 15 2007| Pubmed
  70. DNA microarray technology in toxicogenomics of aquatic models: Methods and applications.
    Ju ZL, Wells MC, Walter RB
    Comparative Biochemistry & Physiology C-toxicology & Pharmacology 145 (1): 5-14 Sp. Iss. SI FEB 2007| Pubmed
  71. From bytes to bedside: Data integration and computational biology for translational cancer research.
    Mathew JP, Taylor BS, Bader GD, et al.
    Plos Computational Biology 3 (2): 153-163 FEB 2007| Pubmed
  72. KLF4 suppresses transformation of pre-B cells by ABL oncogenes.
    Kharas, MG; Yusuf, I; Scarfone, VM; Yang, VW; Segre, JA; Huettner, CS; Fruman, DA
    Blood. 2007 Jan 15;109(2):747-55. Epub 2006 Sep 5.| Pubmed
  73. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability.
    Tompkins, VS; Hagen, J; Frazier, AA; Lushnikova, T; Fitzgerald, MP; di Tommaso, A; Ladeveze, V; Domann, FE; Eischen, CM; Quelle, DE
    J Biol Chem. 2007 Jan 12;282(2):1322-33. Epub 2006 Nov 16.| Pubmed
  74. Chromosomal deletions in bladder cancer: Shutting down pathways.
    Abraham R, Pagano F, Gomella LG, et al.
    Frontiers In Bioscience 12: 826-838 JAN 1 2007| Pubmed
  75. Innovation - The Connectivity Map: a new tool for biomedical research.
    Lamb, J
    Nat Rev Cancer. 2007 Jan;7(1):54-60.| Pubmed
  76. Computational prediction of cancer-gene function.
    Pingzhao Hu, Gary Bader, Dennis A. Wigle and Andrew Emili
    Nature Reviews/Cancer. 2007 Jan; vol 7:23| Pubmed
  77. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.
    Sotillo R, Hernando E, Diaz-Rodriguez E, et al.
    Cancer Cell 11 (1): 9-23 JAN 2007| Pubmed
  78. Targeting cell cycle kinases for cancer therapy.
    de Carcer G, de Castro IP, Malumbres M
    Current Medicinal Chemistry 14 (9): 969-985 2007| Pubmed
  79. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas.
    Assou S, Le Carrour T, Tondeur S, et al.
    Stem Cells 25 (4): 961-973 2007| Pubmed